Published April 17, 2020 | Version v.1
Journal article Open

Diagnosis of Pneumocystis jirovecii Pneumonia in Pediatric Patients in Serbia, Greece, and Romania. Current Status and Challenges for Collaboration

  • 1. National Reference Laboratory for Medical Mycology, Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
  • 2. First Department of Microbiology, School of Medicine, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
  • 3. Laboratory of Antimicrobial Chemotherapy, Ion Ionescu de la Brad University, 700490 Iasi, Romania.
  • 4. Department of Microbiology & Public Health Institute Clinical Center of Nis, Faculty of Medicine, University of Nis, 18000 Nis, Serbia.
  • 5. Haematology Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
  • 6. Institute for Oncology and Radiology of Serbia, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

Description

Abstract: Pneumocystis jirovecii can cause fatal Pneumocystis pneumonia (PcP). Many children have been exposed to the fungus and are colonized in early age, while some individuals at high risk for fungal infections may develop PcP, a disease that is difficult to diagnose. Insufficient laboratory availability, lack of knowledge, and local epidemiology gaps make the problem more serious. Traditionally, the diagnosis is based on microscopic visualization of Pneumocystis in respiratory specimens. The molecular diagnosis is important but not widely used. The aim of this study was to collect initial indicative data from Serbia, Greece, and Romania concerning pediatric patients with suspected PcP in order to: find the key underlying diseases, determine current clinical and laboratory practices, and try to propose an integrative future molecular perspective based on regional collaboration. Data were collected by the search of literature and the use of an online questionnaire, filled by relevant scientists specialized in the field. All three countries presented similar clinical practices in terms of PcP prophylaxis and clinical suspicion. In Serbia and Greece the hematology/oncology diseases are the main risks, while in Romania HIV infection is an additional risk. Molecular diagnosis is available only in Greece. PcP seems to be under-diagnosed and regional collaboration in the field of laboratory diagnosis with an emphasis on molecular approaches may help to cover the gaps and improve the practices. 

Notes

The study is partially supported by an ECMM Pilot Grant, and partially by Grant No 175034 Ministry of Education, Science and Technological Development, Republic of Serbia.

Files

Diagnosis of Pneumocystis jirovecii Pneumonia in ...jof-06-00049 (1).pdf

Files (247.1 kB)

Additional details

Related works

Is identical to
PMC7345889 (pmcid)
Is part of
2309-608X (ISSN)

Funding

Detection of early laboratory fungal biomarkers and it's importance for outcome of invasive fungal infections in Serbia 175034
Ministry of Education, Science and Technological Development